The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function Montero JC, Rodríguez-Barrueco R, Yuste L, Juanes PP, Borges J, Esparís-Ogando A, Pandiella A. Molecular Biology of the Cell 18(2):380-93. FI: 5.979 (Q1) ERK5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis Borges J, Pandiella A, Esparís-Ogando A. Cell Signal 19(7):1473-87. FI: 4.094 (Q2) Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer De Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A. Journal of Clinical Oncology 25(19):2656-63. FI: 17.793 (Q1) Neuregulins and cancer Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A. Clinical Cancer Research 14(11):3237-41. FI: 6.747 (Q1) The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A. Nephrology Dialysis Transplantation 23(11):3403-11. FI: 3.306 (Q1) Synergic antitumoral effect of an oral IGF-IR inhibitor and Herceptin on HER2 overexpressing breast cancer cells Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A. Annals of Oncology 19(11):1860-9. FI: 5.647 (Q1) Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A. PLoS One 4(5):e5565. FI: 4.351 (Q1) ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R. PLoS One 4(7):e6124. FI: 4.351 (Q1) Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A Oncogene , FI: 6,373 (Q1) (D1)
|
